respectively), but P-selectin showed no significant difference. In RA patients, E-selectin was more strongly associated with rheumatoid factor (RF) titre (r=0.43, p=0.003), urinary 8isoprostane (r=0.42, p=0.004), 10-year cardiac risk (r=0.42, p=0.004), BMI (r=0.39, p=0 .008), LDL (r=0.39, p=0 .009) and smoking status (r=0.37, p=0.011), but less strongly with CRP (r=0.32, p=0.033), ESR (r=0.32, p=0 .037) and p=ns) . VCAM in RA was associated with intima-medial thickness (IMT) (r=0.37, p=0.012), vitamin A (r= -0.32, p=0.029), total antioxidant capacity (r=0.30, p=0.042) and BMI (r=0.30, p=0.047) . In a multivariate model, the key factors associated with E-selectin levels in RA were RF titre (p<0.001), BMI (p=0.004), 8-isoprostane (p=0.013) and smoking (p=0.036); VCAM was associated with IMT (p=0.019) only.
Conclusions: The burden of atherosclerosis is increased in middle-aged women with RA. Two biomarkers of endothelial activation, E-selectin and VCAM, were raised in RA patients supporting the notion that patients with vascular changes may be most prone to atherosclerotic complications. E-selectin was associated with disease activity, body mass, lipid peroxidation and smoking, but not with conventional markers of inflammation. Both E-selectin and VCAM may be valuable biomarkers of overall cardiovascular risk in RA.
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A comparison of CKMB and Troponin T in ruling out acute coronary syndrome in low risk chest pain S Knowles, 1 J Mayne, 1 K Frawley, 2 J Baron, 2 N Lawson 1 Department of Biochemistry, 1 Department of Cardiology, 2 Derby Hospitals NHS Foundation Trust, Derby DE22 3NE
We have assessed a published protocol describing the use of CKMB mass as an early rule out marker (6h) for acute coronary syndrome (ACS) in patients who on admission who were ECG and biochemical marker negative. The aim of this study was to determine if CKMB mass or Troponin T could successfully predict outcome and be a reliable earlier ACS rule out than the usual 12 h protocols.
Between March 2005 and May 2006 Total CK, CKMB and Troponin T results (Roche Modular) were performed on serum samples from 136 patients on admission, 6 and 12 hours after onset of pain. These results were assessed against final clinical outcomes to establish which patients would have been correctly identified for admission. The new protocol admission criteria were Troponin T >0.03 mg/L and/or CKMB >5 mg/L at 0 and/or 6 h, or alternatively an increase in CKMB >1.6 mg/L between 0 and 6 h.
Seventeen of the 136 patients were eventually classified as ACS positive. 15 had a 6 h Troponin T >0.03 mg/L. The 2 remaining patients had a 12 h Troponin T >0.03 mg/L, with the 6h value between 0.01 and 0.03 mg/L. 28 patients had a 0h or 6h CKMB >5 mg/L, of which 12 also had an increase in CKMB >1.6 mg/L, however, 3 of the 17 ACS positive patients had negative CKMB results at 0 or 6 h.
This study demonstrates that although a 6h Troponin T or CKMB can detect most patients with ACS a small number of patients will be missed. CKMB did not improve the sensitivity of ACS detection, and was found to be far less specific. Further studies are required to investigate the possible use of a Troponin T >0.01 mg/L at 6 h. Charcot osteoarthropathy is a destructive pathology leading to fractures and deformities, more common in Type 1 diabetic patients. The pathology is unknown, disease process is progressive, and treatment by immobilisation in plaster casts is standard. Treatment is monitored with imaging techniques (X-ray, MRI and bone scintigraphy). We evaluated serum markers of bone metabolism at regular time points as additional tests to determine their use in monitoring the bone disease in acute cases as anabolic/ antiresorptive therapies become available. Serum bone markers overcome the range of variables well known for urine samples.
T21

Serum markers of bone metabolism in monitoring patients with diabetes and Charcot osteoarthropathy
Serum tartrate resistant acid phosphatase 5b isoenzyme (TRAP), a bone resorption marker, and serum Bone Specific Alkaline Phosphatase (BAP), a bone formation marker were evaluated by an ELISA (IDS) using an automatic sample processor (Triturus, Grifol), with our standard procedure for method evaluation. The assay uses an immunoenzymetric methodology with spectrophotometric detection. In order to compare the clinical effectiveness of BAP and TRAP measurements, results were converted to T-Scores using the formula T score = Observed value -mean of the reference range/SD reference range.
Results obtained from a fifty year old diabetic female showed increased bone turnover markers. TRAP levels peaked just when fractures were seen radiologically at 3 months. BAP was generally higher throughout, typically about one and a half times higher than TRAP at this stage. Over the next five months both values fell towards normal limits for this patient group (post menopausal females) with clinical resolution as the joint became stable. Serum markers of bone metabolism appear to reflect changes observed by imaging techniques suggesting they may be useful in monitoring treatment response with different agents, hence potentially reducing radiation exposure.
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Fasting satiety index using peptide YY and ghrelin: an indication of risk of type 2 diabetes in man and impaired glucose metabolism. Obesity is directly associated with the development of insulin resistance and type 2 diabetes. In non-obese subjects the development of type 2 diabetes is more difficult to predict. We devised a fasting satiety index (FSI) as a function of fasting PYY (pg/mL) multiplied by fasting ghrelin (pg/mL), divided by 30,000 in order to normalise a value of a lean, non-insulin resistant person to one. The aim was to assess the efficacy of the FSI in predicting the development of type 2 diabetes.
Methods: Fasting concentrations of PYY and ghrelin were measured in 33 subjects with varying BMIs. 11 subjects had diabetes, four of whom were obese. Fasting serum leptin concentrations and BMI were used as a measure of adiposity. HOMA-IR was used to indicate the degree of insulin resistance.
Findings: We demonstrated a significant negative correlation between FSI and BMI, leptin and HOMA-IR. The FSI in diabetic subjects was significantly lower than in non-diabetics (p=0.003). Using logistic regression analysis the FSI was a statistically significant predictor of type 2 diabetes (p=0.03) whereas BMI was not.
Interpretation: A low FSI may precede the development of type 2 diabetes and may possibly be used as a predictor of type 2 diabetes. This will be of particular use in identifying non-obese subjects at risk of developing type 2 diabetes.
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Reproducibility of the oral glucose tolerance test
T Geberhiwot, C Pitt, A Shafi, A Jones
Department of Clinical Chemistry and Immunology, Heart of England FT, Birmingham B9 5SS
Objective: World Health Organization (WHO) recommends that the diagnosis of diabetes in asymptomatic subjects should involve at least two plasma glucose results. We assessed the reproducibility of oral glucose tolerance test (OGTT).
Methods: Between April and September 2006 we received 1859 requests for OGTT. Plasma glucose was measured by a glucose oxidase method (Roche Modular Analyser). The interassay CVs for glucose were 0.95% and 2.43% at 2.1 and 14.4 mmol/L, respectively. The diagnosis of impaired fasting glucose, impaired glucose tolerance (IGT), and diabetes was based on WHO criteria. Results: 400 (21.5%) of the GTT results were consistent with diabetes mellitus. Forty seven had their OGTT repeated, with a mean duration of 33 days (range 3 -108). In 66% of those with an initial diagnosis of diabetes, the second GTT confirmed this diagnosis. When the initial diagnosis was based on fasting plasma glucose alone (with a normal or IGT glucose value at 2 hrs), just 13% had diabetes confirmed by the second GTT. Given the short time interval between the two tests it would be unlikely that other factors such as life style changes would have made significant impact on the test result.
Conclusions: The oral glucose tolerance test has poor reproducibility. Diagnosis based on a single OGTT is of limited value, especially if only the fasting glucose is elevated.
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The effect of GLP-1 on β β-Cell sensitivity to GIP in type 2 diabetes Objective: Type 2 diabetes mellitus (T2DM) is characterized by reduced circulating GLP-1 levels, and resistance to GIP. Since these two peptides have distinct receptor molecules on β-cells, we hypothesized that restoration of an optimal incretin effect may require augmentation of GIP levels and GIP action, as well as increased levels of GLP-1. Patients and methods: Six obese type 2 diabetic men and 6 matched normal lean controls were each given 4 intravenous infusions of 1000 ml of 10% dextrose over 4 hours in random order on separate days after an overnight fast and included: (1) GLP-1 (7-36) at a rate of 1 pmol/kg/min (2) GIP at a rate of 2 pmol/kg/min (3) GLP-1+GIP and (4) placebo (only 10% dextrose). Glucose, insulin and C-peptide were measured at baseline, 15, 60, 120, 180 and 240 minutes following the start of the infusion. Area under the curves (AUCs) were calculated for all secretory responses according to the trapezoidal rule.
Results ( GLP-1 has previously been shown to promote satiety and suppress energy intake in humans. Furthermore, mice lacking the GIP receptor have higher energy expenditure (EE), a lower respiratory quotient (RQ), use fat as the preferred energy substrate and are resistant to weight gain when fed a high fat diet. We investigated whether exogenous GLP-1 and GIP alter EE and appetite sensations in humans.
Six obese type 2 diabetic men and 6 matched normal lean controls were each given 4 intravenous infusions of 1000ml of 10% dextrose over 4 hours in random order on separate days after an overnight fast and included: (1) GLP-1 (7-36) at a rate of 1 pmol/kg/min (2) GIP at a rate of 2 pmol/kg/min (3) GLP-1+GIP and (4) placebo (only 10% dextrose). EE, measured by indirect calorimetry, and satiety by a series of visual analog scales (VAS) and prospective consumption of food, were studied.
In patients with T2DM overall EE did not change during infusions. In healthy subjects, during GIP infusion there was a significant reduction in EE compared with EE as measured when only dextrose was infused [EE AUC (SEM) 420477.7 (16542.5) kcal.min with GIP vs 379131.2 (15629.7) kcal.min with dextrose only; p=0.017]. No significant changes in RQ between treatment groups were seen.
During co-infusion of GLP-1 and GIP patients with T2DM reported a stronger desire to eat compared with placebo infusion [mean (SEM) VAS score 42.2 (2.8) mm with GLP-1 + GIP vs 32.2 (3.2) with placebo; p=0.015], and healthy subjects reported higher hunger scores when infused with GIP [mean (SEM) VAS score for hunger 40.1 (1.1) mm with GIP vs 30.4 (2.7) mm with dextrose only; p=0.03].
GIP administration reduces EE and increases appetite in lean healthy male subjects. Both these changes occur in a direction that may favour weight gain. Diabetes is a major cause of morbidity and mortality. In England, the National Service Framework for Diabetes (2001) stated "the NHS will develop, implement and monitor strategies to identify people who do not know they have diabetes", in order to promote early diagnosis and treatment and reduce the development of complications. We describe the audit of such a strategy after 2 years.
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Identification of diabetes: 2-year audit of a case-finding protocol
The protocol used was based on one developed and validated in Eire. Patients with 2 or more risk factors for diabetes (selfreferred or identified by primary care staff) were offered a blood glucose measurement. Results over 5.7 mmol/L were investigated further by glucose tolerance testing. The 5.7 threshold was chosen due to its association with an increased risk of macrovascular disease. All diagnoses were made using WHO criteria.
The These results support the concept that a case-finding approach to identify patients with diabetes can lead to diagnosis at an earlier stage of the disease, with a lower incidence of complications at presentation.
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The association of overweight and obesity with an adverse metabolic profile in a cohort of Irish children Introduction/aims: One of the scourges associated with that current epidemic of obesity in Ireland is the rather alarming increase in that prevalence of childhood-onset obesity. In tandem with this observation is the emergence in this cohort of comorbidities such as type 2 diabetes mellitus (T2D), a condition once regarded as the preserve of middle or old age. We undertook a study to elucidate metabolic and biochemical subphenotypes in a cohort of eighteen Irish subjects (male n=6, female n=12) with a history of overweight or obesity in childhood, based on clinical records. In particular we wished to determine if the degree of overweight was associated with adverse metabolic parameters such as fasting glucose, fasting insulin, glucose tolerance, insulin sensitivity, lipid profile and LFTs.
Results: The mean age of the study group was 15.5 years (range 8.6-18.9) and mean BMI SDS was 2.27 (range 1.34-2.77). Within the cohort there were significant correlations between BMI SDS and insulin sensitivity as measured using OGIS (PC = -0.51, p=0.04), fasting insulin (PC = -0.79, p=0.03) and plasma ALT (PC = 0.64, p=0.03). Insulin sensitivity was negatively correlated with total cholesterol (PC = -0.54, p=0.03), though not with HDL-, LDL-cholesterol or triglycerides. Fasting insulin was very strongly correlated with ALT (PC = 0.8, p=0.0006) and Waist:Hip ratio (PC = 0.55, p=0.03).
Discussion: Although the cohort size is small the trends observed in this study suggest that overweight and obesity in childhood may be associated with adverse effects on insulin sensitivity. This could predispose to insulin resistance and ultimately early-onset T2D. In addition, the trend towards higher plasma ALT in overweight subjects suggests the presence of underlying non-alcoholic fatty liver disease. Overall, childhood overweight appears to predict an adverse metabolic profile. Sleep quantity may be important for the maintenance of glucose homeostasis. We decided to investigate the relationship between glucose tolerance, and sleep parameters in a group of patients with obstructive sleep apnoea (OSA). Thirty-three patients with OSA and 11 control subjects were studied. All had overnight polysomnography to quantify sleep disordered breathing. Oral glucose tolerance tests (OGTT) were performed after overnight fasting, and insulin resistance (IR) calculated using the homeostasis model equation (HOMA), and results reported as HOMA IR. Body mass index (BMI) and fat mass were measured.
There were no significant differences between patients and controls for age, BMI, and fat mass. Impaired glucose tolerance (IGT) was seen in 45% (15/33) of patients with OSA, and 36% (4/11) of controls. OSA patients exhibited a trend towards greater IR than controls (HOMA IR 2.3±1.6 [mean±SD] vs. 1.6±1.1 mU/mmol, P=0.076). The apnoea-hypopnoea index (AHI), defined as the mean number of apnoeic and hypopnoeic incidents per hour of sleep, was the only sleep parameter to exhibit a significant difference between patients and controls. Mean AHI was 30±24.8 in OSA, and 2±1 in controls (P=0.006). OSA patients with IGT were more insulin resistant than those with normal OGTT (HOMA IR 2.9±1.9 vs. 1.7±1.0 mU/mmol, P=0.03). There were no significant differences between groups for age or fat mass, but there was a tendency for a higher BMI (31.8±4 vs. 29.0±5.5, p=0.09) in patients with IGT. There were no significant differences in sleep parameters between OSA patients with or without IGT, and no statistical relationship between HOMA IR values and sleep parameters.
Our finding of a high incidence of IGT in patients with OSA supports the findings of other studies that OSA is associated with IGT and IR. We were unable to find a statistical relationship between IR and parameters of sleep disordered breathing.
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Determination of HLA-DQ status in subjects with coeliac disease and equivocal serological markers or histology on jejunal biopsy H R Seddon, 1 P G Hill, 1 G K Holmes 2 Department of Chemical Pathology, 1 Department of Gastroenterology, 2 Derby Hospitals NHS Foundation Trust, Derby DE22 3NE Anti-tissue transglutaminase and anti-endomysial antibodies have a high sensitivity and specificity for coeliac disease (CD). Small intestinal biopsy remains the gold standard for diagnosis, but in some cases biopsy or sero-logy are equivocal. In approximately 90% of people with CD a specific HLA-DQ2 heterodimer is present and most of those who are DQ2 negative are DQ8 positive. Patients negative for HLA-DQ2 or HLA-DQ8 are unlikely to suffer from CD. A diagnostic test kit for HLA-DQ markers is now available. The aim of this study was to investigate whether knowledge of the HLA-DQ status is of value as supporting evidence in diagnosing coeliac disease when serological markers or histology are equivocal.
Methods: HLA-DQ haplotypes were determined in 36 subjects using the Eu-DQ kit by Eurospital (Trieste, Italy).
Results: 17 of 18 (94%) patients with unequivocal CD carried either DQ2 or DQ8. The remaining patient carried one chain of the DQ2 heterodimer, which is consistent with CD. 5 of 6 (83%) patients with characteristic histological changes of CD but negative or equivocal serology carried either DQ2 or DQ8. 11 of 12 (92%) patients with suspected CD, positive serology but negative or equivocal biopsies carried either DQ2 or DQ8.
Conclusions: Two patients were negative for HLA-DQ2 and DQ8 and are therefore unlikely to have CD. This result has been useful in the exclusion of CD in these cases. 92% of patients with negative biopsies and positive serology possessed HLA-DQ2 or HLA-DQ8, suggesting that they are different from the general population and do truly have "potential" coeliac disease. HLA-DQ analysis may provide cost savings and be less invasive than follow-up biopsy in patients with equivocal small bowel histology. There may also be benefits to the screening of Down's syndrome patients and the lifelong exclusion of CD in HLA-DQ2 and DQ8 negative individuals.
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Utility of colorimetric HIAA assay in the screening of carcinoid disease: an audit M S Devgun Department of Biochemistry, Wishaw General Hospital, Wishaw ML2 0DP
An ideal tumour marker can be used for: screening, diagnosis, prognosis, monitoring and recurrence of disease. It should be stable and accurately measurable even in low concentrations. Total hydroxyindole concentration (HIAA) in urine serves as a screening test for carcinoid tumours.
An audit of results was undertaken to determine the usefulness of a colorimetric test for total HIAA in urine to screen malignancy.
The assay uses 1-nitroso-2-naphthol and nitrous acid, reacting with hydroxylated indoles to produce purple colour, using 5-hydroxytryptophan as the reference standard.
215 Specimens were analysed from 185 patients (77 males, 185 females, mean age 55+16 years). 61 specimens had concentrations above the reference limit (<6.4 mmol/mol creatinine). 52 Urines from 38 patients were referred to the regional reference laboratory (reference range 0-50 µmol/day) for confirmation of raised levels.
When comparing concentrations with the reference method, our assay produced 23% false positives and one false negative; only one positive by both methods. When our assay data was converted into mmol/mol creatinine, 75% of specimens were found to be falsely elevated. The hospital's Cancer Registry data showed histologically proven carcinoid disease in 68 tissue biopsies (37 patients). Of the 12 malignant carcinoids identified only 2 were identified biochemically. It is clear that a large portion of carcinoids are not identified by the existing biochemical test for HIAA. Also, not all carcinoid tumours secrete hydroxylated indoles that can be measured. Alternative metabolite specific methods are available for tumour markers such as that for chromogranin-A, these should be used more widely to diagnosis and monitor carcinoid disease.
Colorimetric assay for measuring HIAA is an old technology, is not appropriate, and is unsuitable for screening and monitoring of patients with carcinoid. It is recommended that colorimetric HIAA assay be discontinued in favour of analysis by HPLC and/or metabolite specific assays.
